Acrivon COO reports 613 ACRV shares withheld for taxes, 65K held

Acrivon Therapeutics, Inc. reported a routine insider equity transaction by its Chief Operating Officer.

Rhea-AI Filing Summary

Acrivon Therapeutics, Inc. reported a routine insider equity transaction by its Chief Operating Officer. On 11/14/2025, 613 shares of Acrivon common stock were withheld at a price of $2.24 per share to cover mandatory tax withholding when restricted stock units vested. After this tax-related withholding, the officer beneficially owns 65,308 shares of Acrivon common stock in direct ownership. The filing is administrative in nature and reflects standard equity compensation and tax settlement practices for a senior executive.

Insider Trade Summary

Exercise Price or Tax Liability: 613 shares

Exercise Price or Tax Liability 1 txn

Insider Devroe Eric

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	613	$2.24	$1K

Holdings After Transaction: Common Stock — 65,308 shares (Direct)

Footnotes (1)

1. F1. Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

FAQ

What insider transaction did Acrivon Therapeutics (ACRV) report on this Form 4?

The Chief Operating Officer reported that 613 shares of Acrivon common stock were withheld on 11/14/2025 to satisfy tax obligations upon vesting of restricted stock units.

Who is the reporting person in this ACRV Form 4 filing?

The reporting person is the Chief Operating Officer of Acrivon Therapeutics, Inc., who is an officer of the company and files individually.

How many ACRV shares were withheld for taxes in this transaction?

A total of 613 shares of Acrivon common stock were withheld by the company to satisfy mandatory tax withholding when restricted stock units vested.

At what price were the withheld ACRV shares valued in the Form 4?

The 613 withheld shares of Acrivon common stock were valued at $2.24 per share for the purpose of the reported tax withholding transaction.

How many ACRV shares does the officer own after this Form 4 transaction?

Following the withholding of 613 shares for taxes, the officer beneficially owns 65,308 shares of Acrivon common stock in direct ownership.

Is this ACRV Form 4 transaction a sale of shares on the open market?

No. The explanation states the shares were withheld by Acrivon Therapeutics to satisfy mandatory tax withholding upon the vesting of restricted stock units, rather than being sold in an open-market transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/18/2025 - 04:29 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Devroe Eric

(Last) (First) (Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Acrivon Therapeutics, Inc. [ ACRV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/14/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/14/2025		F(1)		613	D	$2.24	65,308	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

	/s/ Adam D. Levy, Attorney-in-Fact	11/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.